Prognostic significance of microRNA-10b overexpression in breast cancer: a meta-analysis

Wang, N.; Chen, P.; Huang, Li; Wang, T.Z.

doi:10.4238/gmr.15027350

Cited by 10 publications

(6 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This result is consistent with that of Liu et al, 64 who reported that miR-21 is a useful non-invasive biomarker to predict response to chemotherapy in HER2-positive breast cancer. Similarly, Wang et al 65 revealed that increased miR-10b expression might predict poor survival in patients with breast cancer.…”

Section: Discussionmentioning

confidence: 93%

Candidate circulating microRNAs as potential diagnostic and predictive biomarkers for the monitoring of locally advanced breast cancer patients

et al. 2020

View full text Add to dashboard Cite

This study aimed at investigating the expression of candidate microRNAs (miRs), at initial diagnosis, during neoadjuvant chemotherapy, and after the tumor resection in locally advanced breast cancer patients. Plasma samples were collected from locally advanced breast cancer patients (n = 30) and healthy subjects (n = 20) for the detection of candidate miRs’ expression using the real-time quantitative polymerase chain reaction. At initial locally advanced breast cancer diagnosis, the expression of miR-21, miR-181a, and miR-10b was significantly increased, whereas that of miR-145 and let-7a was significantly decreased, compared to the healthy individuals. The diagnostic accuracy of miR-21 was superior to both carcinoembryonic antigen and carcinoma antigen 15-3 as diagnostic biomarkers for locally advanced breast cancer. By the end of the treatment, the expression of altered miRs rebound to control values. The expression levels of candidate plasma miRs are useful diagnostic biomarkers, as well as monitoring a proper response for locally advanced breast cancer patients to the treatment. Furthermore, miR-10b and miR-21 can be considered as predictive biomarkers for progression-free survival.

show abstract

Section: Discussionmentioning

confidence: 93%

Candidate circulating microRNAs as potential diagnostic and predictive biomarkers for the monitoring of locally advanced breast cancer patients

et al. 2020

View full text Add to dashboard Cite

show abstract

“…TGFBR3 inhibits breast cancer progression through TGF-beta signaling (Lee et al, 2010). In addition, other molecules in module 1 such as ADAMTS5 (Fontanil et al, 2017), ARHGAP20 (Asaduzzaman et al, 2017), C2orf88 (Lo et al, 2015), EZH1 (Liu et al, 2012), FAM13A (Goto-Yamaguchi et al, 2018), FGF1 (Slattery et al, 2013), GNAL (Yi et al, 2009), GRAMD3 (Boiles et al, 2015), PELI2 (Zang et al, 2017), PLSCR4 (Sahay et al, 2015), PTPN14 (Belle et al, 2015), RBMS3 (Zhu et al, 2019a), SH3BGRL2 (Alexe et al, 2007;Wen et al, 2018), let-7c (Fu et al, 2017), mir-100 (Jiang et al, 2016b), mir-10b (Wang et al, 2016b), mir-125b (Wang et al, 2019a), mir-139 (Dai et al, 2017), and mir-21 (Yan et al, 2008;Yanwirasti and Arisanty, 2017;Zhu et al, 2019b) have been reported to play important roles in breast cancer. Module 2 had nine nodes, including two miRNAs, five lncRNAs, and two protein-coding genes.…”

Section: Modules In the Dysregulated Network Relate To The Survival Omentioning

confidence: 99%

Dysregulated lncRNA-miRNA-mRNA Network Reveals Patient Survival-Associated Modules and RNA Binding Proteins in Invasive Breast Carcinoma

et al. 2020

View full text Add to dashboard Cite

Breast cancer is the most common cancer in women, but few biomarkers are effective in clinic. Previous studies have shown the important roles of non-coding RNAs in diagnosis, prognosis, and therapy selection for breast cancer and have suggested the significance of integrating molecules at different levels to interpret the mechanism of breast cancer. Here, we collected transcriptome data including long non-coding RNA (lncRNA), microRNA (miRNA), and mRNA for~1,200 samples, including 1079 invasive breast carcinoma samples and 104 normal samples, from The Cancer Genome Atlas (TCGA) project. We identified differentially expressed lncRNAs, miRNAs, and mRNAs that distinguished invasive carcinoma samples from normal samples. We further constructed an integrated dysregulated network consisting of differentially expressed lncRNAs, miRNAs, and mRNAs and found housekeeping and cancer-related functions. Moreover, 58 RNA binding proteins (RBPs) involved in biological processes that are essential to maintain cell survival were found in the dysregulated network, and 10 were correlated with overall survival. In addition, we identified two modules that stratify patients into high-and low-risk subgroups. The expression patterns of these two modules were significantly different in invasive carcinoma versus normal samples, and some molecules were high-confidence biomarkers of breast cancer. Together, these data demonstrated an important clinical application for improving outcome prediction for invasive breast cancers.

show abstract

“…Most of the studies included in this systematic review were performed on miR-10b (5 studies), on miR-21 (11 studies), on miR-34 family (8 studies) and on miR-200 family (10 studies). High level of miR-10b indicates poor prognosis in BC, correlating with angiogenesis and metastatic behaviors (increased tumor size, lymph node positivity and the high Ki-67 score) (139)(140)(141). Importantly, in NOD-SCID mice, the high miR-10b level led to distant metastasis, while in the 4T1 mouse mammary tumor metastasis model, the delivery of AntagomiR speci c for the silencing of miR-10b suppressed the distant metastasis (142,143).…”

Section: Discussionmentioning

confidence: 99%

Preclinical Imaging Evaluation of MiRNAs Delivery and Effects in Breast Cancer Mouse Models: A Systematic Review

Orlandella

Auletta

Greco

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: miRNAs have been defined as a tumor suppressor or oncogene (oncomiR) in several human cancers. We have conducted a systematic review highlighting and specifically focusing in the advancements in preclinical molecular imaging to study in vivo the delivery and the therapeutic efficacy of miRNAs in mouse models of breast cancer.Methods: A systematic review of English articles published in peer-reviewed journals using PubMed® (including MEDLINE®), EMBASE, BIOSIS™, Scopus was performed. Search terms included breast cancer, mouse, mice, microRNA(s) and miRNA(s). The search was focused on the last five years (2015-2021). All studies using miRNA in breast cancer models which included a preclinical imaging evaluation, both in vivo or ex vivo were analyzed. Result: From a total of 2,073 records, 1,221 papers were assessed for full text eligibility, but excluding all those in which there was no use of mouse models of breast cancer, there was not in vivo imaging or ex vivo on whole organs, and without a clear link to a miRNA, our final data extraction was made on a total of 114 manuscripts. The murine genetic background most used in miRNA studies have been resulted to be the Balb/C (46,7%). Regarding cell lines, MDA-MB-231 parental and derived cells were used in most experiments (62,5%). The most used model was the i.v. metastatic model (46,8%), which was obtained via intravenous injection (68,9%) in the tail vein. The modulation of miRNA was obtained mainly by stable transfection with specific lentiviral plasmid or DNA constructs in luciferase- labelled BC cells (54,4%). Bioluminescence resulted the most used tool (64%) and was used as a surrogate of tumor growth for efficacy treatment or for the evaluation of tumorigenicity in miRNA transfected cells (29,9%); for tracking, evaluation of engraftment and for response to therapy in metastatic models (50,6%).Conclusion: this review provides a systematic and focused analysis of all the information currently available and related to the imaging protocols to test miRNA therapy in in vivo mice model of BC and has the purpose to provide an important tool to suggest the best pre-clinical imaging protocol on currently available evidences.

show abstract

Prognostic significance of microRNA-10b overexpression in breast cancer: a meta-analysis

Cited by 10 publications

References 21 publications

Candidate circulating microRNAs as potential diagnostic and predictive biomarkers for the monitoring of locally advanced breast cancer patients

Candidate circulating microRNAs as potential diagnostic and predictive biomarkers for the monitoring of locally advanced breast cancer patients

Dysregulated lncRNA-miRNA-mRNA Network Reveals Patient Survival-Associated Modules and RNA Binding Proteins in Invasive Breast Carcinoma

Preclinical Imaging Evaluation of MiRNAs Delivery and Effects in Breast Cancer Mouse Models: A Systematic Review

Contact Info

Product

Resources

About